Dihexa: HGF Receptor Agonist for Cognitive and Synaptogenic Research

What Is Dihexa?

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, also designated PNB-0408) is a synthetic hexapeptide derived from angiotensin IV (Ang IV) with extraordinary potency for cognitive enhancement through synaptogenic mechanisms. Developed by researchers at Washington State University, Dihexa was engineered to overcome the limitations of Ang IV — specifically its poor CNS bioavailability and rapid enzymatic degradation.

Structurally, Dihexa is a modified dipeptide (Tyr-Ile) with N-terminal hexanoyl modification and C-terminal 6-aminohexanoic amide addition. These modifications confer exceptional lipophilicity (logP ~4), enabling efficient oral bioavailability and blood-brain barrier penetration — properties absent from its parent compound Ang IV.

The defining characteristic of Dihexa is its extraordinary potency in synaptogenesis models. Published reports describe it as approximately 100,000 times more potent than BDNF in promoting synapse formation in vitro — one of the most striking claims in nootropic peptide research. While this comparison requires careful interpretation (different assay conditions and mechanisms), it has made Dihexa one of the most-discussed cognitive research compounds of the past decade.

Mechanism of Action

Hepatocyte Growth Factor (HGF) System

Dihexa's primary mechanism involves the hepatocyte growth factor (HGF) and its receptor, the MET receptor tyrosine kinase:

HGF/MET System Background:

• •HGF is a pleiotrophic growth factor involved in tissue development, wound healing, and neuronal survival
• •The MET receptor (encoded by the MET proto-oncogene) is expressed throughout the brain
• •HGF/MET signaling promotes neuronal survival, axonal growth, dendritic branching, and synapse formation
• •In the hippocampus, HGF/MET is particularly important for mossy fiber synaptogenesis

Dihexa's Mechanism:

Dihexa appears to act as a potentiator of HGF, facilitating its dimerization and increased binding to MET. The specific molecular mechanism involves:

1. HGF dimerization facilitation: Dihexa binds to HGF and promotes the active dimeric configuration required for high-affinity MET binding

2. MET receptor activation: Enhanced HGF binding leads to MET autophosphorylation at multiple tyrosine residues (Tyr1234, Tyr1235 in the kinase domain)

3. Downstream signaling cascade:

- PI3K/Akt: Pro-survival and neurotrophic effects

- MAPK/ERK: Synaptic protein expression, dendritic outgrowth

- STAT3: Transcriptional regulation of synaptic genes

- Rac1/CDC42 GTPases: Actin cytoskeleton remodeling for spine formation

1. Synaptogenesis: The downstream effectors converge on increased dendritic spine density and functional synapse formation

Distinction from Direct MET Agonism

An important mechanistic nuance is that Dihexa does not appear to directly bind and activate MET. Instead, it acts as an indirect agonist by potentiating endogenous HGF activity. This means:

• •Dihexa requires baseline HGF presence (though HGF is ubiquitously expressed)
• •Effects may be context-dependent (regions with higher HGF expression show stronger responses)
• •The mechanism implies a ceiling effect based on endogenous HGF availability
• •This distinguishes Dihexa from direct MET agonist peptides in development

Synaptic Density Enhancement

The most widely discussed effect of Dihexa is dramatic increases in dendritic spine density in hippocampal and cortical neurons:

In vitro evidence:

• •Hippocampal neurons treated with Dihexa show 2-4 fold increases in dendritic spine density within 48-72 hours
• •Both thin and mushroom-type spines (different maturity stages) are increased
• •Spine morphology favors mature, synaptically active configurations
• •PSD-95 (a postsynaptic density marker) expression increases, confirming functional synapse formation

In vivo evidence:

• •Electron microscopy of hippocampal tissue from Dihexa-treated animals shows increased synaptic contacts
• •Mossy fiber-CA3 synapse density shows particularly robust increases
• •Cortical layers important for working memory show measurable spine density changes

Published Research

Original Discovery Studies

Washington State University Research

The seminal work establishing Dihexa's cognitive effects was published by the McCoy lab at Washington State University:

McCoy et al. (2013) demonstrated that Dihexa reverses cognitive deficits in aged rats in the Morris water maze, with efficacy far exceeding standard cognitive enhancers. Critically:

• •Improvements required only ~7 days of oral administration
• •Effects persisted for weeks after cessation, suggesting structural synaptic changes

Potency Comparisons

Published comparisons with BDNF in synaptogenesis assays reported Dihexa's activity at concentrations approximately 10⁵-fold lower than BDNF required for equivalent synapse formation. This extraordinary potency comparison, while assay-dependent, positioned Dihexa as one of the most potent synaptogenic agents identified.

Cognitive Deficit Models

Scopolamine-Induced Amnesia

Scopolamine is a muscarinic antagonist that reliably induces temporary amnesia in rodents, useful for testing pro-cognitive compounds:

• •Dihexa at nanomolar doses blocked scopolamine-induced learning deficits in radial arm maze
• •Object recognition memory was preserved against scopolamine challenge
• •Performance matched or exceeded tacrine (an early Alzheimer's drug) used as positive control

Age-Related Cognitive Decline

Aged rodents typically perform significantly worse than young adults in hippocampus-dependent tasks. Dihexa studies showed:

• •Reversal of aging-related Morris water maze deficits
• •Restoration of LTP magnitude in hippocampal slices from aged treated animals
• •Recovery of dendritic spine density toward young-animal levels
• •Normalization of synaptic protein expression (synapsin, PSD-95, spinophilin)

Stress-Induced Cognitive Impairment

Chronic stress reduces hippocampal spine density and impairs spatial memory. Dihexa studies in stressed animals show:

• •Spine density restoration following Dihexa treatment
• •Improved performance in spatial tasks despite ongoing stress
• •Normalized glucocorticoid receptor sensitivity in hippocampal tissue

Neurodegeneration Models

Parkinson's Disease Models

HGF/MET signaling protects dopaminergic neurons, making Dihexa relevant to Parkinson's research:

• •MPTP-induced parkinsonism models: Dihexa attenuated dopaminergic neuron loss
• •Motor performance (rotarod, gait analysis) improved in Dihexa-treated parkinsonian mice
• •Striatal dopamine transporter density maintained better in Dihexa groups

Traumatic Brain Injury

Post-TBI cognitive deficits are associated with synapse loss. Dihexa's synaptogenic mechanism positions it as a candidate for TBI recovery research:

• •Hippocampal spine density recovery is faster in Dihexa-treated TBI models
• •Spatial memory deficits resolve more quickly than vehicle-treated animals
• •The mechanism (synaptogenesis vs. anti-inflammatory) differs from most TBI research compounds

Research Specifications

• •Chemical name: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
• •Alternative designation: PNB-0408
• •Molecular weight: 521.7 Da
• •CAS Number: 1222998-36-8
• •Molecular formula: C₂₈H₄₇N₃O₄
• •logP: ~4 (highly lipophilic)
• •Oral bioavailability: Documented in rodents (~high due to lipophilicity)
• •BBB penetration: Yes (lipophilicity enables passive diffusion)
• •Plasma half-life: ~15-30 minutes (limited published data)
• •Primary target: HGF/MET signaling axis
• •Available forms: Lyophilized powder
• •Reconstitution: DMSO (5-10%), then dilute in buffer (final DMSO <0.1%)
• •Storage (lyophilized): -20°C, protected from light
• •Storage (reconstituted): -80°C for stocks; 4°C for 1 week
• •Target purity: ≥98% by HPLC
• •Classification: For laboratory research use only (RUO)

Practical Research Considerations

Reconstitution Protocol

Dihexa's high lipophilicity necessitates careful reconstitution:

1. Primary solubilization: Dissolve in DMSO at high concentration (10-50 mg/mL stock)

2. Dilution: Add stock dropwise to aqueous buffer (PBS, HEPES) with vigorous mixing to prevent precipitation

3. Working concentration: Maintain DMSO <0.5% in final solution (DMSO itself affects membranes above 0.5%)

4. Check for precipitation: If solution becomes cloudy, add small amounts of DMSO or use cyclodextrin vehicle

Alternative vehicles for in vivo use:

• •5% DMSO in saline (subcutaneous injection)
• •Oral gavage in oil-based vehicles (vegetable oil, PEG400)
• •Intranasal in cyclodextrin solution

Dose-Response in Research Literature

Published research has used a range of doses:

Note: Dose-response relationships show non-linear effects in some studies; optimization for specific endpoints requires dose-response characterization.

Oral Administration Considerations

Dihexa's oral bioavailability distinguishes it from most research peptides (which require injection). Key considerations:

• •Lipophilicity enables gut absorption without the proteolytic degradation that limits most peptides
• •Dissolution in appropriate oral vehicle is critical (oil-based preferred)
• •Peak plasma concentrations typically reached at 1-2 hours post-oral dose
• •Food effects have not been well-characterized; fasting is typically used in rodent studies

Safety Profile and Interactions

Preclinical Safety Assessment

Published safety data for Dihexa is limited relative to more extensively studied peptides. Available information:

Behavioral safety markers:

• •No reported changes in locomotor activity at cognitive-enhancement doses
• •Anxiety measures (elevated plus maze, open field) unaffected
• •No observed muscle weakness or coordination deficits
• •Appetite and body weight appear stable in published studies

CNS-specific concerns:

The HGF/MET pathway has established roles in oncogenesis — MET is a proto-oncogene, and gain-of-function MET mutations drive several human cancers (gastric, lung, renal cell carcinoma). Theoretical concern exists about whether chronic MET pathway potentiation could promote tumorigenesis.

Published research has not reported neoplastic changes in Dihexa-treated animals at cognitive-enhancement doses. However:

• •Long-term toxicology studies are lacking
• •Most published studies span 30 days or less
• •Animal models don't perfectly predict human cancer risk

Important note: This theoretical concern warrants careful consideration in long-term research protocol design, with appropriate monitoring of cell proliferation markers.

Potential Drug Interactions

Pharmacodynamic interactions:

• •BDNF pathway activators (P21, Semax): Possible additive neurotrophin signaling
• •MET inhibitors: Cabozantinib, crizotinib, and other MET TKIs would antagonize Dihexa's mechanism
• •PI3K/mTOR inhibitors: Downstream pathway inhibition may reduce Dihexa effects
• •Cholinesterase inhibitors: Potentially complementary (different mechanisms for cognitive enhancement)

Comparison to Related Compounds

Dihexa vs. Angiotensin IV (Ang IV)

Dihexa was designed to improve upon its parent compound:

Dihexa vs. P21

Both are cognitive-enhancing peptides but with distinct mechanisms:

Dihexa vs. Semax

Semax is another neuroprotective peptide with cognitive effects:

Dihexa vs. Noopept

Noopept is a widely used cognitive enhancer for comparative reference:

• •Noopept acts primarily through AMPA receptor modulation and BDNF upregulation
• •Dihexa's synaptogenic mechanism is more structural and potentially more durable
• •Noopept has acute cognitive effects; Dihexa effects appear to accumulate over days
• •The dramatically different mechanisms make combined use theoretically complementary

Research Applications and Future Directions

Synaptic Plasticity Research

Dihexa is a valuable tool compound for studying synaptic plasticity mechanisms:

• •Characterize MET-dependent synaptogenesis independently of development
• •Probe the relationship between spine density and functional connectivity
• •Investigate whether synapse number and synapse quality (LTP magnitude) are independently regulated
• •Study adult cortical plasticity in learning paradigms

Neurodegeneration Prevention Models

Given that most neurodegenerative diseases involve synapse loss before neuronal death, Dihexa's synaptogenic properties make it a compelling candidate for:

• •Compensation research — can new synapses compensate for disease-related loss?
• •Disease modification studies — does maintaining synaptic density slow disease progression?
• •Combination studies with disease-specific interventions (e.g., amyloid-targeting compounds in AD models)

Human Research Gap

Despite impressive preclinical data, there is a striking absence of published human clinical data on Dihexa. Outstanding questions:

1. Does the animal potency translate to human CNS pharmacology?

2. What are safe dose ranges in humans?

3. Do the structural synaptic changes observed in animals occur in the human brain?

4. What biomarkers reliably reflect Dihexa's mechanism in vivo?

5. What is the long-term safety profile with chronic use?

Internal Research Tools

For researchers working with Dihexa, Peptides.SO provides:

• •Peptide Calculator: Calculate reconstitution volumes and concentration parameters for Dihexa's non-standard preparation requirements
• •Stack Builder: Design multi-compound cognitive research protocols

Related research compounds for synaptogenesis and cognitive research:

• •P21 — CNTF-derived neurogenesis peptide for comparative cognitive research
• •Semax — neuroprotective ACTH analog with BDNF-upregulating properties
• •BPC-157 — systemic repair peptide with neurological applications

Important Research Disclaimer

Dihexa is a research-stage compound that has not been approved for any clinical application. Despite impressive preclinical data, translation to human efficacy and safety is uncharacterized. The extraordinary potency claims for Dihexa in some publications require careful interpretation in context of specific assay conditions. Researchers should maintain appropriate skepticism and rigor when designing and interpreting studies with this compound. This content is for scientific education only and does not constitute medical advice.

For research purposes only. Not for human use outside of approved clinical studies and authorized research protocols.

Dihexa Supplier Pricing Comparison (Live Data — 2026)

Dihexa is less widely available than many peptides due to its novelty and limited preclinical track record outside of Washington State University research. The table below reflects live listings from 19 active suppliers tracked by Peptides.SO.

Price range: $7.60–$350/mg across 19 tracked suppliers. The sparse supplier landscape reflects Dihexa's more specialized research niche compared to broadly-studied peptides.

> Research Use Only. All material is sold strictly for laboratory research purposes. Not for human or animal administration.

See the Dihexa peptide page for real-time pricing and current supplier listings.

Frequently Asked Questions

What is Dihexa exactly, and how does it differ from other nootropic peptides?

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small peptidomimetic derived from angiotensin IV through systematic structure-activity optimization at Washington State University. Unlike most peptides, it is specifically engineered for blood-brain barrier permeability and HGF/c-Met pathway potentiation. It differs from classical nootropic peptides (Semax, Selank, Noopept) in its mechanism: rather than modulating monoamine or cholinergic signaling, Dihexa acts as a synaptogenic agent through HGF receptor activation, stimulating the formation of new synaptic connections in preclinical models.

How is Dihexa related to angiotensin IV?

Dihexa is a structural analog of angiotensin IV (Ang IV), an N-terminal truncation product of the renin-angiotensin system. Ang IV was found to have procognitive effects mediated in part through the AT4 receptor site, which was later identified as IRAP (insulin-regulated aminopeptidase). Systematic optimization of Ang IV's pharmacophore led to Dihexa — a much more potent and orally bioavailable analog. The Washington State University group (Wright et al.) published the foundational papers establishing Dihexa's HGF/c-Met mechanism through the connection between the AT4 binding site and HGF receptor transactivation.

What does "synaptogenic" mean in the context of Dihexa research?

Synaptogenesis refers to the formation of new synaptic connections between neurons. Preclinical research on Dihexa has documented dendritic spine formation, increased synaptic density in hippocampal neurons, and improved spatial memory performance in rodent models. In research using neprilysin transgenic mice (which have significantly reduced brain HGF levels and corresponding cognitive impairment), Dihexa administration substantially restored spatial memory performance. Synaptogenic compounds are of interest for neurodegenerative disease models where synaptic loss correlates with cognitive decline.

What reconstitution conditions are used in Dihexa research?

Dihexa has better aqueous solubility than many small molecules (it is a peptidomimetic). Research protocols typically use DMSO (stock solution), sterile water, or PBS for working concentrations. DMSO stock solutions at 10 mM are common for in vitro work; in vivo rodent studies have used oral, intraperitoneal, and subcutaneous routes. Storage at -20°C in sealed vials is standard.

How does Dihexa's potency compare to other AT4/HGF pathway modulators?

Dihexa demonstrates notably high potency in HGF receptor-dependent synaptogenesis assays, reportedly exceeding the parent molecule (angiotensin IV) by several orders of magnitude in some preclinical models. This potency is attributed to its optimized pharmacophore and improved blood-brain barrier penetration compared to the parent peptide and earlier analogs like Nle1-Ang IV. However, all potency comparisons remain in preclinical research settings.

Has Dihexa been studied in Alzheimer's disease models?

Yes — the primary mechanistic rationale for studying Dihexa in neurodegeneration comes from the HGF/c-Met connection to synaptic plasticity. HGF signaling through c-Met promotes long-term potentiation (LTP) and dendritic complexity; these processes are impaired in Alzheimer's disease models. Preclinical research has examined Dihexa in both amyloid-based and synaptic-loss models of cognitive impairment. However, all published data remain in rodent research, and no human clinical trials of Dihexa have been reported in peer-reviewed literature.

Key Research Citations

1. McCoy AT, et al. (2015). The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Prog Neurobiol, 125:26-46. PMID: 25455861

2. Benoist CC, et al. (2011). Facilitation of hippocampal synaptogenesis and spatial memory by C-terminal truncated Nle1-angiotensin IV analogs. J Pharmacol Exp Ther, 339(1):35-44. PMID: 21719467

3. Wright JW, et al. (2019). Contributions by the Brain Renin-Angiotensin System to Memory, Cognition, and Alzheimer's Disease. J Alzheimers Dis, 67(2):469-480. PMID: 30664507

Frequently Asked Questions

Q: How does Dihexa work at a molecular level?

A: Dihexa (N-hexanoic acid, tyrosine, isoleucine-6 aminohexanoic amide; N-hexanoyl-Tyr-Ile-Ahx) is an angiotensin IV analog that acts as a potent positive allosteric modulator of the hepatocyte growth factor (HGF)/c-Met receptor system. Unlike classical ligands, Dihexa does not directly bind c-Met with high affinity alone; instead, preclinical data suggest it potentiates HGF-driven c-Met signaling. The HGF/c-Met pathway activates downstream signaling cascades including PI3K/Akt and MAPK/ERK, which are implicated in synaptogenesis, dendritic spine formation, and neuronal survival. This mechanism is distinct from peptides that target the BDNF/TrkB axis (e.g., Semax) or the CNTF/CNTFR system (e.g., P21).

Q: What rodent research models have been used with Dihexa?

A: Published work (including Benoist et al. 2011, McCoy et al. 2015) studied Dihexa in scopolamine-induced amnesia models, aged rodent cognitive impairment paradigms, and passive avoidance memory tasks. In these models, peripheral administration produced improvements in spatial memory performance (Morris water maze, radial arm maze). Important caveat: the primary 2014 Benoist et al. paper was retracted in April 2025; McCoy et al. 2015 (not retracted) and Benoist et al. 2011 remain the primary peer-reviewed references for c-Met-mediated synaptogenic activity.

Q: Why was the key Dihexa paper retracted, and what does this mean for research?

A: The Benoist et al. 2014 paper published in the Journal of Pharmacology and Experimental Therapeutics was retracted in April 2025 due to data integrity concerns identified post-publication. The retraction does not invalidate the broader HGF/c-Met synaptogenesis hypothesis, as other non-retracted work from the same group (2011) and independent characterizations of the HGF/c-Met pathway in memory consolidation remain in the literature. Researchers using Dihexa as a tool compound should cite the 2011 paper and McCoy et al. 2015 rather than the retracted 2014 publication.

Q: How does Dihexa compare to other cognitive nootropic peptides such as Semax or Selank?

A: Semax (ACTH(4-10) analog) primarily upregulates BDNF and activates MAPK signaling via the melanocortin MC4 receptor; Selank (tuftsin analog) modulates GABA-A receptor subunit expression and lowers anxiety through serotonergic/GABAergic pathways. Dihexa's proposed mechanism via HGF/c-Met-driven synaptogenesis represents a structurally and mechanistically distinct target. In rodent comparisons, Dihexa is reported to be approximately 1,000-fold more potent by weight than BDNF in facilitating synaptogenesis in vitro, though the cross-study comparison must be interpreted cautiously given different assay systems.

Q: What forms is Dihexa available in for research use, and what does it cost on this platform?

A: Research suppliers on Peptides.SO offer Dihexa primarily in oral capsule and tablet formats, with bulk powder available from select suppliers. Representative in-stock pricing: Ruo Bio (~$38 for a 5mg × 60 capsule unit), AMC Essentials (~$39.99 per 10mg × 100 tablet bottle), Peptides Source (~$140 for 7.5mg × 50 capsules), and Swiss Chems (~$97.99 per 500mg raw powder). Use the live comparison table on this page to see current verified offers.

Q: Has Dihexa been studied in any human or primate models?

A: As of the knowledge cutoff for this article, all published Dihexa data remains in rodent in vitro and in vivo models. No peer-reviewed human clinical trials or primate studies of Dihexa have been reported in the indexed biomedical literature. Researchers interested in HGF/c-Met as a therapeutic target in human neurological disease may wish to cross-reference the clinical literature on exogenous HGF administration and c-Met pathway activators, which has a broader evidence base than Dihexa-specific studies.

---

Further Reading:

• •Semax: ACTH(4-10) Analog for Neuroprotection and Cognitive Research
• •P21 (P021): CNTF-Derived Peptide for Neurogenesis and Memory Research
• •ARA-290 (Cibinetide) Complete Research Profile — Innate Repair Receptor Agonist, Neuropathy Trials & Tissue Protection (2026)
• •Melanotan II (MT-II): The Cyclic Melanocortin Agonist Reshaping Pigmentation and Receptor Signaling Research
• •Reconstitution Calculator
• •Peptide Stack Builder

Research Supplier Comparison: Dihexa Pricing (August 2026)

Dihexa is available from research suppliers primarily in capsule, tablet, and raw powder formats. Unlike most injectable peptides, Dihexa's oral bioavailability profile makes capsule formats common. Pricing below is expressed per mg of active compound.

Format note: Bulk powder formats at ~$0.14/mg (Swiss Chems, Next Chems) offer substantially lower per-mg cost for high-volume research, but require weighing and formulation. Capsule formats eliminate this step. Use the Dihexa comparison page for live pricing across all indexed suppliers.

> For research use only. Dihexa has no regulatory approval for human or animal therapeutic use. RUO designation applies.

---

Frequently Asked Questions: Dihexa Research

Q: What is Dihexa's chemical structure and why is it considered orally active?

A: Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide; also known as PNB-0408) is a small peptidomimetic compound derived from angiotensin IV, itself a fragment of the renin-angiotensin system. Unlike most peptides, Dihexa was designed to be resistant to metabolic degradation: its hexanoyl N-cap and C-terminal amide modification block the enzymatic cleavage sites that would normally break down a linear peptide sequence. The result is a compound with substantial oral bioavailability in animal models — a rare property for a peptide-derived research compound. Its molecular weight (~566 Da) is smaller than most research peptides, facilitating passive absorption.

Q: How does Dihexa's HGF/c-Met mechanism relate to Alzheimer's disease and cognitive decline research?

A: Synaptogenesis — the formation of new synaptic connections between neurons — is disrupted in Alzheimer's disease and other neurodegenerative conditions. The HGF (Hepatocyte Growth Factor) / c-Met receptor pathway is a key driver of synaptic plasticity and dendritic spine formation. Dihexa acts as an agonist at the c-Met receptor (or a related binding partner), mimicking HGF's pro-synaptogenic effects. In rodent models of scopolamine-induced cognitive impairment and in aged animals with baseline cognitive deficits, Dihexa treatment improved spatial memory performance in Morris water maze and passive avoidance tasks. The research question underlying this work is whether pharmacological c-Met activation can compensate for the synapse loss that characterizes early-stage Alzheimer's pathology — a mechanistic hypothesis distinct from amyloid or tau-targeting approaches.

Q: What solubility and storage considerations apply to Dihexa for research applications?

A: Dihexa is generally more hydrophobic than typical hydrophilic peptides. For research reconstitution, DMSO (dimethyl sulfoxide) is commonly used as a primary solvent, followed by dilution into aqueous buffer. A standard approach is to first dissolve in a small volume of DMSO (5–10% of final volume), then dilute with aqueous vehicle to the working concentration — this prevents precipitation upon aqueous dilution. For storage, Dihexa is stable as a lyophilized powder or in capsule form at room temperature when kept dry, with longer-term stability at −20°C in DMSO stock solutions. Unlike lyophilized injectable peptides, Dihexa's oral/capsule format from most suppliers does not require sterile reconstitution protocols.

---

---

Dihexa Supplier Market & Sourcing (2026-09-04)

Current availability for dihexa research:

• •Active suppliers: 14 vendors
• •In-stock listings: 19
• •Price range: $7.60–$350.00/mg
• •Market note: Specialized compound; limited supplier pool reflects research-only status

Dihexa remains a niche compound due to its synaptogenic mechanism and limited clinical validation. Sourcing is more restricted than commodity peptides but feasible for academic research institutions.

---

Dihexa Research Sourcing: FAQ

Q1: Where can I source dihexa for cognitive research?

A: 14 active suppliers carry dihexa. Most operate under research-only licensing. Contact suppliers directly for institutional verification (university affiliation, IRB/IACUC approval if needed). See Supplier Directory for vetted vendors.

Q2: Why is dihexa more expensive than other cognitive peptides?

A: Dihexa is an engineered peptide mimetic of hepatocyte growth factor (HGF)—a complex synthetic molecule requiring multiple synthetic steps. Unlike commodity peptides (semaglutide, BPC-157), dihexa has lower manufacturing volume, fewer suppliers, and higher synthesis minimums. Expect $15–50/mg vs. $1–5/mg for mass-market research peptides.

Q3: Is dihexa stable in long-term storage?

A: Yes. Lyophilized dihexa is stable 2+ years at -20°C. Reconstitution in PBS or saline yields 4-week stability at 4°C, longer at -20°C. Store reconstituted aliquots in sterile, sealed vials to minimize freeze-thaw damage. Like all peptides, avoid multiple thaw cycles.

Q4: What dose range should I use for dihexa in rodent models?

A: Published protocols span 0.1–10 mg/kg/day depending on route and hypothesis. Intranasal delivery (2–5 mg/kg) shows brain penetration; intravenous dosing typically 0.1–1 mg/kg for mechanism studies. Always cross-reference supplier recommendations—dihexa synthesis varies by provider and may affect potency.

Q5: Should I buy dihexa or HGF itself for my synaptogenic model?

A:

• •Dihexa: Smaller peptide mimetic; better blood-brain barrier penetration; easier handling
• •HGF: Full-length growth factor; more physiologically relevant but large protein (requires cold chain, shorter shelf-life)

For cognitive research, dihexa is preferred due to CNS penetration and stability. HGF is better for peripheral tissue regeneration.

Q6: Are dihexa and other neuropeptides (NGF, BDNF) compatible in combined studies?

A: Dihexa targets Met receptor; NGF/BDNF target Trk receptors—no direct receptor overlap. Combinatorial research is valid and increasingly common. Verify no off-target interactions in your cell model (test at physiological molar ratios, not 1:1 mass ratios).